Mycotopia Therapies, Inc. financial data

Symbol
TPIA on OTC
Industry
Medicinal Chemicals & Botanical Products
Location
480 22 Nd Street, Heyburn, ID
State of incorporation
NV
Fiscal year end
December 31
Former names
20/20 Global, Inc. (to 5/19/2021)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 6.07 % -73.3%
Debt-to-equity -173 % -36.8%
Return On Equity 61.2 % -46.2%
Return On Assets -83.5 % +80.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.99M shares -59.8%
Common Stock, Shares, Outstanding 5.48M shares -63.2%
Entity Public Float 1.55M USD -75.1%
Common Stock, Value, Issued 5.48K USD -63.2%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 1.33M USD +71.3%
Operating Income (Loss) -1.33M USD -71.3%
Nonoperating Income (Expense) -321K USD +55.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.65M USD -10.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.65M USD -10.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 438K USD -53.7%
Assets, Current 203K USD -35.9%
Property, Plant and Equipment, Net 0 USD -100%
Assets 1.64M USD +417%
Accrued Liabilities, Current 450K USD
Liabilities, Current 5M USD +143%
Liabilities 5M USD +143%
Retained Earnings (Accumulated Deficit) -10.3M USD -19%
Stockholders' Equity Attributable to Parent -3.36M USD -93.3%
Liabilities and Equity 1.64M USD +417%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -73.7K USD -155%
Net Cash Provided by (Used in) Financing Activities 165K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 467M shares +367%
Common Stock, Shares, Issued 5.48M shares -63.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 215K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 202K USD -36.2%
Deferred Tax Assets, Valuation Allowance 552K USD +51.9%
Cash and Cash Equivalents, Period Increase (Decrease) 215K USD
Deferred Tax Assets, Gross 552K USD +51.9%
Depreciation 498 USD -33.3%
Deferred Tax Assets, Operating Loss Carryforwards 268K USD +29.5%
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 6.95M USD +0.52%
Interest Expense -243K USD -47.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares